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Introduction
There is increasing evidence that higher levels of high sensitivity 
C-reactive protein (hs-CRP) is a marker of inflammation and a po-
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Background and Objectives: Serum high sensitivity C-reactive protein (hs-CRP) is a marker of inflammation and may lead to the devel-
opment of atherosclerosis, adversely affecting mortality. The aim of this study was to evaluate the relationship between baseline hs-CRP 
level and 12-month clinical outcomes in patients with acute myocardial infarction (AMI) undergoing percutaneous coronary intervention 
(PCI) according to their body mass index (BMI) status.
Subjects and Methods: Using data from the Korea Acute Myocardial Infarction Registry from November 2005 to September 2008, a to-
tal of 8174 consecutive AMI patients were studied. Cox proportional hazard model revealed that higher baseline levels of hs-CRP was as-
sociated with 12-month all-cause mortality (p=0.045). To further understand this association, patients were divided into 3 groups based 
on their body mass index: 1) overweight/obese, 2) normal weight, and 3) underweight patients. Then each group was stratified into quar-
tiles based on their hs-CRP. 
Results: In overweight/obese patients, Cox model showed significant association of hs-CRP with 12-month mortality when adjusted for 
age and gender (p<0.001), however, after adjustment with multiple covariates, mortality was highest in the 4th quartile {HR 2.382, (1.079-
5.259), p=0.032} though statistically insignificant (p=0.172). We observed no significant association of serum hs-CRP with 12-month mor-
tality in normal weight (p=0.681) and underweight (p=0.760) patients.
Conclusion: Higher baseline hs-CRP level (≥4.08 mg/dL) in overweight/obese AMI patients showed significant association with 12-month 
all-cause mortality independent of other prognostic markers. (Korean Circ J 2012;42:164-172)
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tential independent predictor of cardiovascular disease, as it may 
play a role in the development of atherosclerosis, adversely affect-
ing mortality.
1)2) Rate of obesity is increasing globally where stud-
ies have shown association of body weight as assessed by body 165 Khurshid Ahmed, et al.
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mass index (BMI) with clinical outcomes after percutaneous coro-
nary intervention (PCI) in acute myocardial infarction (AMI) pa-
tients.
3) Previous reports have also indicated that hs-CRP level is 
correlated with BMI and fat distribution.
4)5) The mechanism for el-
evation of plasma hs-CRP in obese subjects could be through a high 
production of cytokines, e.g., interleukin-1β (IL-1β), interleukin-6 (IL-
6) and tumor necrosis factor-α (TNF-α), by excess adipose tissue 
which could induce high hs-CRP production in liver.
4) 
Curently there is no data available evaluating the relationship 
between higher baseline hs-CRP levels, body mass index (BMI) sta-
tus, and adverse outcomes in patients with AMI undergoing PCI. 
Therefore, in the present study we attempted to assess the associ-
ation between baseline hs-CRP level and 12-month clinical out-
comes in patients with AMI.
Subjects and Methods
This retrospective study was carried out at The Heart Center of 
Chonnam National University Hospital, Korea. The permission to car-
ry out the study had been sought from the hospital authorities (IRB 
No.05-49) and informed consent obtained from the patients. Patient 
medical documents were used to obtain the demographic data, clini-
cal characteristics and relevant laboratory results. Patients were en-
rolled in the registry after admission to participating hospitals with 
a suspected diagnosis of AMI.
Korea Acute Myocardial Infarction Registry
The Korea Acute Myocardial Infarction Registry (KAMIR) is a pro-
spective, multicenter, observational registry designed to examine 
current epidemiology in hospital management and outcome of pa-
tients with AMI in Korea. The registry included 52 community and uni-
versity hospitals capable of primary PCI with one-year clinical follow 
up. Data was collected at each site by a well-trained study coordi-
nator based on a standardized protocol.
6-8)
Study population
A total of 10974 consecutive patients with AMI (both ST-segment 
elevation MI and non-ST-segment elevation MI) undergoing PCI 
from November 2005 to September 2008 were assessed in this 
study. Patients with unknown BMI (n=395) and missing hs-CRP (n= 
2405) data were excluded from this study; hence the total study 
population was 8174 patients. The aim was to evaluate the impact 
of baseline hs-CRP on 12-month clinical outcomes according to BMI 
status. Initially we studied this in terms of the total study popula-
tion. Then, according to BMI categories suggested by the World He-
alth Organization for Asian population, the total study population was 
divided into three groups that included 1) overweight/obese (BMI 
≥23 kg/m
2, n=5647), 2) normal-weight (BMI 18.5 to 22.9 kg/m
2, n= 
2246) and 3) underweight (BMI <18.5 kg/m
2, n=281).
9) Each group 
was then stratified into quartiles based on their hs-CRP levels.
Definitions and clinical endpoints  
A final diagnosis of AMI was made by the European Society of Car-
diology/American College of Cardiology (ESC/ACC) diagnostic criteria 
for AMI.
10) BMI was calculated as weight (kg) divided by height 
squared (m
2). Diabetes mellitus (DM) was defined as requiring the 
use of oral hypoglycaemic agent or insulin to lower blood glucose 
levels. Hypertension was defined as patient systolic blood pressure 
>140 mm Hg and/or diastolic blood pressure >90 mm Hg at rest, 
over a series of repeated measurements, or after treatment with an-
ti-hypertensive medications. For diabetics and patients with chronic 
renal disease, hypertension was defined as systolic blood pressure 
≥130 mm Hg and/or diastolic blood pressure ≥80 mm Hg. Hyper-
lipidemia was defined as patient total cholesterol level >200 mg/dL 
or treatment with a lipid-lowering agent. Coronary artery disease 
(CAD) was defined as patient having a history of myocardial in-
farction (MI) revascularization procedure, or obstructive CAD.
Peripheral blood samples were obtained on admission using di-
rect venipuncture. Blood samples were centrifuged and serum was 
removed and stored at a temperature of -700°C until the assay for 
sugar and proteins was performed. Absolute creatine kinase-MB lev-
els were determined by radioimmunoassay (Dade Behring, Inc., Mi-
ami, FL, USA). Cardiac specific troponin I levels were measured us-
ing a paramagnetic particle, chemiluminescent immunoenzymatic 
assay (Beckham, Coulter, Inc., Fullerton, CA, USA). Twelve-hour fasting 
serum levels of total cholesterol, triglyceride, and low and high den-
sity lipoprotein-cholesterol were measured by standard enzymatic 
methods. Blood sample for hs-CRP was obtained on admission 
and was analyzed turbidimetrically with sheep antibodies against 
human CRP; this has been validated against the Dade Behring 
method. Each group was divided into quartiles based on their hs-
CRP levels. Overweight/obese quartiles were: first quartile <0.2 mg/
dL, n=1370, second quartile ≥0.2 to <0.82 mg/dL, n=1451, third qu-
artile ≥0.82 to <4.08 mg/dL, n=1413 and fourth quartile ≥4.08 mg/
dL, n=1413. Normal-weight quartiles were: first quartile <0.2 mg/dL, 
n=548, second quartile ≥0.2 to <0.92 mg/dL, n=575, third quartile 
≥0.92 to <5.23, n=563 mg/dL and fourth quartile ≥5.23 mg/dL, 
n=563. Underweight quartiles were: first quartile <0.31 mg/dL, n= 
70, second quartile ≥0.31 to <1.54 mg/dL, n=70, third quartile ≥1.54 
to <8.76 mg/dL, n=71 and fourth quartile ≥8.76 mg/dL, n=70. 
Two-dimensional echocardiography was performed in all pa-
tients and left ventricular ejection fraction (LVEF) was assessed us-
ing a modified Simpson’s biplane method. The morphology in cor-
onary angiography was classified by criteria from the American 166  hs-CRP and BMI in AMI Patients
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College of Cardiology/American Heart Association (ACC/AHA).
11) 
The degree of coronary flow was classified by Thrombolysis in Myo-
cardial Infarction (TIMI) score. The presence of left main coronary 
artery stenosis was defined as a luminal stenosis ≥50%. Multives-
sel disease was defined as the presence of a lesion with >50% di-
ameter stenosis in a non-infarct related coronary artery. Successful 
PCI was defined as TIMI flow 3 with residual stenosis ≤50% in the 
infarct related artery. In-hospital complications included atrio-ven-
tricular block, bradycardia, ventricular tachycardia/ventricular fibrill-
ation, atrial fibrillation, no reflow, dissection, cardiogenic shock, acu-
te renal failure, metabolic acidosis/lactic acidosis.
Major advense cardiac event (MACE) were defined as all-cause 
death, recurrent MI, or repeat revascularization.
The primary endpoint of this study was all-cause mortality at 
12-month clinical follow up. All data were recorded on a standardiz-
ed, electronic, web based registry at http://www.kamir.or.kr.
Statistical analysis
SPSS 17.0 for windows (SPSS, Inc., Chicago, IL, USA) was used for 
all analyses. Continuous variables were presented as the mean±SD; 
comparisons were conducted by one-way ANOVA test. Discrete 
variables were presented as percentages and frequencies; compar-
isons were conducted by chi-square statistics. A p<0.05 was con-
sidered statistically significant. Cox regression analysis was per-
formed to identify a model with independent predictive factors 
including determination of a hazard ratio and its 95% confidence 
interval (CI) for each variable in the model. Cox analysis was per-
formed to identify variables that most affected the hazard ratio of 
hs-CRP, with a cut off at p<0.20 for entry into the model. 
Results
A total of 8,174 AMI patients, mean age=62.7±12.4 years and 
76% male gender (n=6217), were stratified into quartiles based on 
their hs-CRP level to study their 12-month clinical outcomes. Tw-
elve-month all-cause death and 12-month composite of MACE in-
creased as the value of hs-CRP increased from 1st to 4th quartile. 
Cox proportional hazard analysis showed 12-month mortality to be 
highest in patients of 4th quartile {HR=2.80 (1.335-5.873), p=0.006} 
followed by 3rd quartile {HR=2.495 (1.186-5.248), p=0.016}. It was 
statistically significant among hs-CRP quartiles (p=0.045). Indepen-
dent factors for 12-month mortality were age greater than 60 years, 
in-hospital complications, Killip class >1, use of statin, heart rate 
>100 beats/min, N-terminal pro-B-type natriuretic peptide (NT-
proBNP) >3000 pg/mL, left ventricular ejection fraction (LVEF) <55% 
and creatinine clearance <60 min/mL (data not provided).
As the 12-month mortality was statistically borderline significant 
among hs-CRP quartiles in the total study population, we sought 
to further evaluate this finding by dividing the total study popula-
tion into three groups based on their BMI. Overweight and obese 
patients were grouped together as there was no baseline significant 
difference in their 12-month all-cause mortality (p=0.076, data not 
provided).
Overweight/Obese group
(n=5647, mean age=60.4±12.2 years, 75.2% male)
Baseline clinical characteristics and laboratory findings of this gr-
oup are presented in Table 1 and 2 respectively. Overweight/obese 
patients with higher hs-CRP (i.e., 2nd, 3rd and 4th quartiles) were 
older, more often female, had higher Killip classes, heart rate and NT-
proBNP; and had lower blood pressure, LVEF and creatinine clear-
ance. They were associated with higher incidence of DM, hyperten-
sion, CAD, heart failure and cerebrovascular disease. Statin use was 
not significant among the quartiles (p=0.702). As per past regular 
medication history, 7.15% of the patients at the time of admission 
were on statin (n=404). 
Coronary angiographic findings are presented in Table 3. Multi-
vessel involvement, ACC/AHA lesion type C, and Pre-PCI TIMI flow 
grade 0 were observed to increase with an increase in hs-CRP. Post-
PCI TIMI flow grade 3 was nearly similar among all quartiles. PCI suc-
cess rate decreased and in-hospital complication rate increased with 
increasing hs-CRP.
Table 4 shows the clinical outcomes during the 12-month follow-
up. In-hospital death, composite MACE at 1 month and 12 months, 
and mortality at 1 month and 12 months were more frequent with 
increasing hs-CRP levels. Twelve-month mortality increased as the 
value of hs-CRP increased; 2.0% (n=27) in 1st, 2.5% (n=37) in 2nd, 
4.4% (n=62) in 3rd and highest 6.6% (n=94) in the 4th quartile. 
Cox proportional hazard model was implemented to identify the 
independent predictors of mortality at the 12-month clinical follow-
up. Serum hs-CRP quartiles showed significant association with 
12-month mortality when adjusted for age and gender (p<0.001). 
With quartile 1 as a reference, the risk of 12-month mortality was 
higher in the 3rd quartile {2.153 (1.369-3.384), p=0.001} and 4th 
quartile {3.268 (2.129-5.016), p<0.001}. After adjustment with mul-
tiple covariates, 12-month mortality was highest in patients within 
the 4th quartile compared to other patients {hazard ratio (HR) 2.382 
(1.079-5.259), p=0.032} though statistical significance was not 
achieved (p=0.172). Independent factors for 12-month mortality 
were old age (>60 years), heart rate >100 beats/min, LVEF <55%, 
creatinine clearance <60 min/mL and in-hospital complications. The 
variables included in Cox model were age, male gender, heart rate, 
systolic blood pressure, smoking history, history of hypertension, di-
abetes mellitus, coronary artery disease, cerebrovascular disease and 167 Khurshid Ahmed, et al.
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heart failure, LVEF, Killip classes >1, glucose, total cholesterol, tri-
glyceride, creatinine clearance, NT-proBNP, left main and multivessel 
involvement, pre-TIMI flow grade 0, post-TIMI flow grade 3, ACC/
AHA lesion type C, PCI success rate, in-hospital complications and 
use of statin.
 
Normal-weight group
(n=2246, mean age=66.5±11.6 years, 68.6% male) 
Patients were also stratified into quartiles based on hs-CRP level 
to evaluate their 12-month clinical outcomes. Patients with higher 
hs-CRP were found to be older (p<0.001), with increased heart rate 
(p=0.015) and higher Killip classes (p=0.002). They had more associ-
ation with diabetes mellitus (p=0.019), hypertension (p=0.049), heart 
failure (p=0.001) and peripheral vascular disease (p=0.001). Creati-
nine clearance, LVEF and high-density lipoprotein cholesterol de-
creased with higher hs-CRP (p<0.001, p<0.001 and p=0.001 respec-
tively). NTproBNP showed an increasing trend among quartiles (p< 
0.001). Total cholesterol, triglyceride and low density lipoprotein-
cholesterol (LDL-C) were also significant among quartiles (p<0.001, 
p=0.001 and p=0.001 respectively). They were more associated 
with ACC/AHA lesion type C, multivessel involvement, pre-TIMI flow 
grade 0 and in-hospital complications. Twelve-month composite 
of MACE (p=0.009) and all-cause death (p<0.001) increased as the 
value of hs-CRP increased from 1st to 4th quartile. Cox proportional 
hazard model showed 12-month mortality to be statistically insig-
nificant among hs-CRP quartiles in this group (p=0.681). The vari-
ables included in the model were age, DM, hypertension, hyperlip-
idemia, heart failure, peripheral vascular disease, smoking history, 
clinical presentation ST-elevation MI, total cholesterol, triglyceride, 
creatinine clearance, NT-proBNP, systolic blood pressure, heart rate, 
in-hospital complications, Killip class >1, LVEF <55%, pre-procedure 
TIMI grade 0 flow, ACC/AHA lesion type C, multivessel involvement, 
and use of statin.
Underweight group
(n=281, mean age=71.5±11.0 years, 64.4% male) 
Patients from this study were additionally divided into quartiles 
based on hs-CRP level to study their 12-month clinical outcomes. 
The variables included in the model were age, systolic blood pressure, 
LVEF <55%, glucose, total cholesterol, LDL-C, creatinine clearance, 
Table 1. Baseline clinical characteristics of overweight/obese patients according to levels of high sensitivity C-reactive protein 
Variables 
Quartile 1
(<0.2 mg/dL)
n=1370
Quartile 2
(≥0.2 - <0.82 mg/dL)
n=1451
Quartile 3
(≥0.82 - <4.08 mg/dL)
n=1413
Quartile 4 
(≥4.08 mg/dL)
n=1413
p
Age (years) 59.18±11.99 59.96±12.16 60.97±12.02 61.58±12.62 <0.001
Male gender, n (%) 1061 (77.5) 1113 (76.8) 1037 (73.4) 1032 (73.0) 0.010
Body mass index (kg/m
2) 25.72±2.61 25.60±2.52 25.66±2.55 25.77±3.23 0.367
Systolic BP (mm Hg) 132.69±27.41 133.41±27.63 129.78±29.05 125.42±27.26 <0.001
Heart rate (beats/min) 74.40±17.45 75.71±17.18 76.82±19.44 79.23±26.27 <0.001
LVEF (%)  54.95±10.92 53.45±11.12 52.38±11.54 49.17±11.95 <0.001
Killip >1, n (%) 270 (19.7) 247 (17.0) 301 (21.3) 368 (26.0) <0.001
Past history, n (%)
Smoking  888 (64.8) 931 (64.1) 887 (62.7) 803 (56.8) <0.001
Diabetes mellitus 342 (24.9) 379 (26.1) 430 (30.4) 414 (29.3) 0.003
Hypertension 641 (46.8) 719 (49.5) 749 (53.0) 722 (51.1) 0.009
Hyperlipidemia  162 (11.8) 163 (11.2) 162 (11.5) 138 (9.8) 0.310
Coronary artery disease 243 (17.7) 177 (12.2) 196 (13.9) 203 (14.4) <0.001
Heart failure  6 (0.4) 10 (0.7) 27 (1.9) 20 (1.4) 0.001
CVD 51 (3.7) 71 (4.9) 71 (5.0) 98 (6.9) 0.002
PVD 5 (0.4) 6 (0.4) 13 (0.9) 15 (1.1) 0.054
Family history of CAD, n (%) 109 (8.0) 130 (9.0) 99 (7.0) 117 (8.3) 0.270
Statin use 1040 (76) 1127 (77.7) 1085 (76.8) 1087 (76.9) 0.702
Clinical presentation, n (%)
STEMI 886 (64.7) 963 (66.4) 898 (63.6) 917 (64.9) 0.470
Non-STEMI 484 (35.3) 488 (33.6) 515 (36.4) 496 (35.1) 0.470
Data are expressed as mean±SD or as number (percentage). BP: blood pressure, CAD: coronary artery disease, CVD: cerebrovascular disease, LVEF: left ven-
tricular ejection fraction, PVD: peripheral vascular disease, STEMI: ST elevation myocardial infarction168  hs-CRP and BMI in AMI Patients
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NT-proBNP, smoking history, heart failure, post-procedure TIMI gr-
ade 3, PCI success rate, and in-hospital complications. Age, NT-pro-
BNP, Killip class >1 and in-hospital complications increased with in-
creasing levels of hs-CRP (p=0.006, p<0.001, p=0.009 and p=0.032 
respectively), while creatinine clearance decreased with rising level 
of hs-CRP (p=0.001). Systolic blood pressure, LVEF, total cholesterol 
and post-TIMI flow grade III were statistically significant among 
the quartiles (p=0.043, p=0.023, p=0.038 and p=0.002 respectively). 
Twelve-month composite of MACE increased as the value of hs-
CRP increased from 1st to 4th quartile, but it was statistically in-
significant (p=0.382), and twelve-month all-cause death showed 
no association among quartiles (p=0.079). Cox proportional hazard 
model showed 12-month mortality to be statistically insignificant 
among hs-CRP quartiles in this group as well (p=0.760). 
Fig. 1 shows adjusted survival curves of 12-month mortality in 
hs-CRP quartiles in (A) total study population, (B) overweight/obese 
group, (C) normal-weight group and (D) underweight group.
Discussion
This study demonstrated that higher baseline hs-CRP level (≥4.08 
mg/dL) in overweight/obese AMI patients showed significant asso-
ciation with 12-month all-cause mortality independent of other 
prognostic markers.
Table 2. Laboratory characteristics of overweight/obese patients according to high sensitivity C-reactive protein levels
Variables 
Quartile 1 
 (<0.2 mg/dL) 
n=1370
Quartile 2 
(≥0.2 - <0.82 mg/dL)
n=1451
Quartile 3
(≥0.82 - <4.08 mg/dL)
n=1413
Quartile 4
(≥4.08 mg/dL)
n=1413
p
CK-MB (U/L) 162.34±357.40 171.68±290.18 161.26±326.0 170.05±309.94 0.76
Troponin I (ng/mL) 46.54±86.23 53.59±96.32 46.33±94.11 52.91±94.15 0.11
NT-proBNP (pg/mL) 629.27±2398.85 1166.35±3779.03 1807.84±5119.69 2909.69±5828.27 <0.001
Creatinine (mg/dL) 1.14±1.38 1.08±0.81 1.18±1.26 1.23±1.15 0.005
Creatinine clearance (min/mL) 80.70±32.95 78.89±32.11 75.36±33.21 73.03±31.53 <0.001
Glucose (mg/dL) 163.26±68.10 168.71±72.44 170.71±75.55 175.15±86.02 0.001
Total cholesterol (mg/dL) 189.69±42.02 193.98±44.43 187.03±42.77 182.13±44.50 <0.001
Triglyceride (mg/dL) 139.95±101.10 148.41±134.20 132.45±95.69 133.84±114.36 0.001
LDL-C (mg/dL) 121.87±39.88 124.48±38.56 121.26±47.45 117.07±43.13 <0.001
HDL-C (mg/dL) 46.21±24.84 44.80±17.91 43.99±20.48 42.76±17.31 <0.001
Data are expressed as mean±SD or as number (percentage). CK-MB: creatinine kinase-MB, HDL-C: high density lipoprotein–cholesterol, LDL-C: low density 
lipoprotein-cholesterol, NT-pro BNP: N-terminal pro-brain natriuretic peptide
Table 3. Angiographic findings and procedural results of overweight/obese patients according to high sensitivity C-reactive protein levels
 Variables 
Quartile 1  
(<0.2 mg/dL)
n=1370
Quartile 2  
(≥0.2 - <0.82 mg/dL) 
n=1451         
Quartile 3  
(≥0.82 - 4.08 mg/dL) 
n=1413
Quartile 4  
(≥4.08 mg/dL)
n=1413
p
Infarct-related artery, n (%)
    Left main stem 15 (1.1) 14 (1.0) 26 (1.8) 22 (1.6) 0.14
    Left anterior descending artery 626 (45.7) 679 (46.8) 620 (43.9) 665 (47.1) 0.46
    Left circumflex artery 250 (18.2) 238 (16.4) 247 (17.5) 229 (16.2) 0.42
    Right coronary artery 461(33.6) 496 (34.2) 478 (33.8) 472 (33.4) 0.94
ACC/AHA lesion type C, n (%)              556 (40.6) 584 (40.2) 629 (44.5) 686 (48.5) <0.001
PCI with stent, n (%) 1268 (92.5) 1351 (93.1) 1301 (92.0) 1290 (91.3) 0.212
Multivessel involvement, n (%) 656 (47.9) 764 (52.6) 813 (57.5) 848 (60.0) <0.001
Pre-PCI TIMI flow grade 0, n (%)              538 (39.3) 615 (42.4) 590 (41.7) 670 (47.4) 0.002
Post-PCI TIMI flow grade III, n (%) 1210 (88.4) 1281 (88.3) 1210 (85.6) 1252 (88.6) 0.004
PCI success rate, n (%) 1311 (95.7) 1361 (93.8) 1315 (93.1) 1321 (93.5) 0.004
In-hospital complications, n (%) 120 (8.8) 117 (8.1) 157 (11.1) 226 (16.0) <0.001
*in-hospital complications include atrio-ventricular block, bradycardia, ventricular tachycardia/ventricular fibrillation, atrial fibrillation, cardiogenic shock, 
acute renal failure, metabolic acidosis/lactic acidosis, cerebrovascular event or infection/sepsis. ACC/AHA: American college of cardiology/American heart 
association, PCI: percutaneous coronary intervention, TIMI: Thrombolysis in Myocardial Infarction169 Khurshid Ahmed, et al.
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Over the past few years, it has become increasingly clear that in-
flammation plays a pivotal role in cardiovascular disease, and in-
creased circulating inflammation markers may be predictive of car-
diovascular events.
12)13) Among the inflammation markers available, 
hs-CRP is one of the independent predictors of cardiovascular ev-
ents.
14)15) Adiposity is an inflammatory condition and IL-6, TNF-α and 
hs-CRP levels are positively correlated with adipocyte size.
4)15)16) 
These cytokines induce insulin resistance in adipose cells by inhib-
Table 4. Clinical outcomes and major adverse cardiac events (MACEs) during follow-up and at 12 months in overweight/obese patients
Outcomes, n (%)
Quartile 1  
(<0.2 mg/dL)
n=1370
Quartile 2  
(≥0.2 - <0.82 mg/dL)
n=1451           
Quartile 3  
(≥0.82 - <4.08 mg/dL)
n=1413
Quartile 4
(≥4.08 mg/dL)
n=1413
p
In-hospital death 14 (1.0) 17 (1.2) 31 (2.2) 47 (3.3) <0.001
The composite of MACE at 1 month 37 (2.7) 50 (3.4) 53 (3.7) 86 (6.0) <0.001
All cause death rate at 1 month 22 (1.6) 26 (1.8) 43 (3.0) 67 (4.7) <0.001
The composite of MACE at 12 months 121 (8.8) 136 (9.4) 149 (10.5) 197 (13.9) <0.001
All cause death rate at 12 months 27 (2.0) 37 (2.5) 62 (4.4) 94 (6.6) <0.001
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p=0.172
Quartile 1&4
p=0.032
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hs-CRP (quartiles)
1st quartile <0.2 mg/dL
2nd quartile 0.2-0.82 mg/dL
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4th quartile >4.08 mg/dL
hs-CRP quartiles 
(under weight)
1st quartile <0.31 mg/dL
2nd quartile 0.31-1.54 mg/dL
3rd quartile 1.54-8.76 mg/dL
4th quartile >8.76 mg/dL
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3rd quartile 0.92-5.23 mg/dL
4th quartile >5.23 mg/dL
A  
C  
B  
D  
Fig. 1. Adjusted Cox proportional hazard survival curves for 12-month all-cause mortality and high sensitivity C-reactive protein (hs-CRP) quartiles in AMI 
patients undergoing PCI in (A) total study population, overall p=0.045, between 1st and 2nd quartile p=0.093, between 1st and 3rd quartile p=0.015 and 
between 1st and 4th quartile p=0.007; (B) overweight/obese group, overall p=0.172, between 1st and 2nd quartile p=0.213, between 1st and 3rd quartile 
p=0.150 and between 1st and 4th quartile p=0.032; (C) normal-weight group, overall p=0.681, between 1st and 2nd quartile p=0.824, between 1st and 
3rd quartile p=0.337 and between 1st and 4th quartile p=0.623; and (D) underweight group, overall p=0.760, between 1st and 2nd quartile p=0.293, be-
tween 1st and 3rd quartile p=0.469 and between 1st and 4th quartile p=0.658. AMI: acute myocardial infarction, PCI: percutaneous coronary intervention.170  hs-CRP and BMI in AMI Patients
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iting insulin signaling.
17)18) CRP along with IL-6 and other cytokines/ 
adipokines could be deleterious on the arterial wall since it has been 
found to directly promote endothelial cell inflammation and ath-
erosclerotic processes.
19)20) Thus, the link between adiposity, plaque 
accumulation/progression/rupture and atherothrombotic events, 
especially AMI, might be explained by higher levels of systemic in-
flammation and their chronic effect on coronary atherosclerosis over 
time. 
Marsik et al.
2) report that patients with CRP concentrations >5 
mg/L at the time of hospital admission had a 50% to 330% increase 
in risk of death from any cause. This increase in risk was present in 
both short-term and long-term follow-ups, and rose in magnitude 
as concentrations of CRP increased to >10 mg/L. Another study by 
Koenig et al.
1) deals with the issue of hs-CRP as a predictor of death 
in the monitoring of trends and determinants in cardiovascular dis-
ease. Augsburg general population cohort in Southern Germany. In 
this prospective evaluation of 3620 initially healthy men followed 
over a 7.1-year period, 408 deaths occurred. After adjustment for 
age, smoking, hypertension, hyperlipidemia, diabetes, obesity and 
socioeconomic markers, those with baseline hs-CRP concentra-
tions >3 mg/L had a 2-fold increase in risk of total mortality. Some 
studies have shown that higher BMI is associated with higher CRP 
concentrations even among young adults 17 to 39 years of age. These 
findings suggest a state of low-grade systemic inflammation in 
obese patients.
21)
As previously reported by Sutter et al.
22) it is known that increased 
levels of hs-CRP are greatly associated with extensive tissue de-
struction or infarct size. In such situations with more severe inflam-
mation and extensive tissue damage, the relationship between ad-
verse outcomes and CRP level might be considered independent 
from BMI status.
The present study shows that hs-CRP concentrations in the obese 
rise with increasing age, diabetes mellitus, hypertension, coronary ar-
tery disease, heart failure and cerebrovascular disease reaffirming 
data from earlier studies.
23-25) A prospective study by Bruci et al.
26) on 
329 patients with myocardial infarction at the time of admission 
showed CRP to be associated with a strong, positive graded increase 
in the risk of heart failure and death independently of known risk 
indicators. Ninety-four patients (29%) were in Killip class greater 
than 1 at presentation, and greater Killip class was associated with 
increased CRP. Interestingly, a study in Cairo by Fareed et al. noted 
that patients with hs-CRP -17 mg/L were prone to heart failure (at 
this value sensitivity=88%, specificity=51.2%). Our findings are in 
agreement with a recently published report that showed a trend to 
decreasing values of LVEF in relation to higher CRP levels.
27) The sig-
nificant relationship between CRP and LVEF suggests the implication 
of inflammatory mechanisms in left ventricular dysfunction and in 
the pathogenesis of congestive heart failure, independently of the 
underlying atherosclerotic burden.
Angiographic findings of multivessel involvement, frequency of 
ACC/AHA lesion type C and subsequently higher pre-TIMI grade 0 
flow, lower procedure success rate and higher complications sup-
port the previous study findings on acute coronary syndrome that 
demonstrated multiple complex stenoses with high plaque burden 
suggesting a pan-coronary involvement.
28)
This study showed a negative relation of smoking with hs-CRP 
in the overweight/obese subset. The mechanism whereby smoking 
is related to CRP concentration is unclear, but it may be multi-facto-
rial, involving bronchial injury, endothelial activation and systemic 
inflammation.
29) Use of a statin is a negative predictor of 12-month 
mortality in total study population. However, there was no signifi-
cant association of statin use and hs-CRP levels in higher BMI pa-
tients though earlier studies have shown that statin reduces hs-
CRP levels.
30)31) This could be due to relatively small number of pa-
tients on a statin at the time of admission (7.15%) or unavailability 
of follow-up hs-CRP data in our registry. Moreover, in Anglo-Scan-
dinavian Cardiac Outcomes Trial: Lipid Lowering Arm trial neither ba-
seline nor on-treatment CRP provided useful information about the 
efficacy of statin treatment to reduce cardiovascular events beyond 
LDL-C reduction.
32)
Study limitations 
This study should be interpreted in the light of the following li-
mitations. This is not a randomized trial, but a retrospective evalu-
ation on a large-scale multi-center registry. Blood samples for hs-
CRP were obtained at the time of admission, hence higher levels of 
hs-CRP in our study may not be associated with myocardial necro-
sis.
33) The time of onset and size of the myocardial infarction may 
also increase the hs-CRP levels. However, we did not determine the 
serial changes in hs-CRP concentration after AMI. Other inflam-
matory markers, such as IL-6, TNF-α or Lipoprotein-associated Phos-
pholipase A2 (Lp-PLA2) that could have added more robust evid-
ence of other inflammatory pathways associated with poor out-
come were not a part of this study. Extreme variations in hs-CRP 
levels that could have made a difference in standard deviation in 
each group have not been excluded from this study.
Conclusions 
Higher baseline hs-CRP level (≥4.08 mg/dL) in overweight/obese 
AMI patients showed significant association with 12-month all-
cause mortality independent of other prognostic markers. We sug-
gest further long term evaluation with serial changes in hs-CRP con-
centration after AMI and other inflammation markers to clearly 
elucidate its role in more diverse population. 171 Khurshid Ahmed, et al.
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